title: Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
abstract: The efficacy and side effects of hydroxyurea in young children with sickle cell disease are unknown. The authors followed-up eight young children (mean age 3.7 years) during therapy with hydroxyurea for an average of 137 weeks. Total and fetal hemoglobin levels rose with hydroxyurea therapy. Hospital admission rates and total hospital days decreased during hydroxyurea therapy. No unexpected toxicity occurred, and growth and development were unaffected. This pilot study suggests that hydroxyurea is safe and effective in young children with sickle cell disease.
authors.affiliation: Department of Hematology/Oncology, Children's Hospital Oakland, California 94609, USA.
authors.forename: C
authors.initials: C
authors.lastname: Hoppe
authors.forename: E
authors.initials: E
authors.lastname: Vichinsky
authors.forename: K
authors.initials: K
authors.lastname: Quirolo
authors.forename: J
authors.initials: J
authors.lastname: van Warmerdam
authors.forename: K
authors.initials: K
authors.lastname: Allen
authors.forename: L
authors.initials: L
authors.lastname: Styles
mesh_terms: D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy*; D000986:Antisickling Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005319:Fetal Hemoglobin / Q000378:metabolism; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000986:Antisickling Agents; D006454:Hemoglobins; D005319:Fetal Hemoglobin; D006918:Hydroxyurea